On May 26, 2026, Niowave Inc. broke ground on its second actinium-225 production facility in Lansing, Michigan. The $75 million investment will house multiple proprietary superconducting linear accelerators alongside processing and quality systems designed to support scalable Ac-225 production. The facility is expected to begin operations in 2028.
The construction follows two landmark supply agreements: a 10-year deal with AstraZeneca expanded in December 2025, and a global supply agreement with Novartis announced in February 2026. These contracts anchor the supply of Ac-225 for two of the world's largest radiopharmaceutical development programs.
Actinium-225 is an alpha-emitting radioisotope that has emerged as one of the most promising components in targeted cancer therapy. Unlike beta-emitting isotopes, Ac-225 delivers high-energy alpha particles directly to malignant cells while minimizing damage to surrounding healthy tissue. This precision makes it ideal for next-generation radioligand therapies (RLTs).
However, Ac-225 has historically faced severe supply constraints. The isotope is primarily obtained as a decay product of thorium-229, a scarce material sourced from aging nuclear fuel stocks. Niowave's approach — using superconducting linear accelerators to produce Ac-225 through a proprietary nuclear reaction process — represents a fundamentally different and more scalable production model.
1. Isotope Intermediate Processing: As Ac-225 production scales, there is growing demand for specialized intermediate processing, quality testing, and logistics services. CDMOs with capabilities in radiopharmaceutical handling, cold-chain management, and GMP-compliant isotope processing are positioned to capture new business.
2. Radiopharmaceutical Manufacturing: More Ac-225 supply enables more radiopharmaceutical candidates to advance through clinical development. CDMOs specializing in radioligand conjugation, lyophilization, and sterile fill-finish for radiopharmaceuticals will see increased demand.
3. Tech Transfer Opportunities: Niowave's accelerator-based production approach is itself a technology platform. As the company expands, there are opportunities for tech transfer partnerships focused on quality control methods, analytical validation, and regulatory compliance.
4. Supply Chain Diversification: With AstraZeneca and Novartis now locked into long-term supply commitments, other pharmaceutical companies developing radiopharmaceutical pipelines will seek alternative Ac-225 sources, creating opportunities for secondary isotope suppliers.
The global radiopharmaceuticals market is projected to grow at a compound annual rate exceeding 10% through 2030, driven by expanding oncology indications. Novartis's Pluvicto has demonstrated commercial viability, and Ac-225-based therapies represent the next frontier. As Niowave's new facility comes online in 2028, the global Ac-225 supply picture will look fundamentally different. For CDMO partners and API intermediates suppliers, the message is clear: the radiopharmaceutical revolution is moving from clinical promise to commercial reality.
